Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Sepura, ReNeuron, Angel Bio ...

Wed, 16th May 2012 15:18

Sepura, the developer and supplier of TETRA digital radios, has acquired 3T Communications, a supplier of TETRA infrastructure, for an initial cash consideration of 8m euros. The final price could increase by up to 5m euros, depending on 3T's trading performance. Austrian firm 3T designs and implements small to mid size TETRA systems predominantly for the commercial sector, including enterprise customers such as Shell, RWE, Bayer and BMW. The acquisition is expected to be earnings enhancing to Sepura for the current financial year and beyond.Electrical component supplier e2v technologies has agreed the sale of its non-core businesses, for a total cash consideration of £14.7m, to a newly formed company, SGX Sensortech, backed by Baird Capital Partners. The non-core businesses comprise: e2v Scientific Instruments, based in High Wycombe; the industrial gas sensing business based at e2v's Chelmsford facility; and e2v micro-sensors SA based in Neuchetel Switzerland. They provide a range of professional sensing products for x-ray spectroscopy and gas sensing for automotive and environmental safety applications.ReNeuron, the Surrey based stem cell developer, has signed a cell manufacturing contract with Angel Biotechnology, a bio-pharmaceutical contract manufacturer, to perform drug product manufacturing services as part of the PISCES Phase I clinical trial of ReNeuron's ReN001 stem cell therapy for stroke victims. The remaining dose cohorts in the current study are expected to complete treatment within the next twelve months, and the company maintains its belief that the study will be ready for application for phase two during the course of next year.Arden Partners, an institutional stockbroking company, has revealed that trading during the six months ended April 30th has been better than anticipated with revenues and profitability ahead of budget. Since the year end the company has increased the number of brokerships to 34 and this number is expected to grow in the medium term. The average market capitalisation of its clients is now £195m. Performance in the second half of the year will depend on market conditions, which given the situation in Europe dictates a need for some caution, the firm warned. The company intends to return to the dividend list from the interim period. Yell, a digital services provider, has acquired Moonfruit, the UK's leading DIY website and online shop builder, for £18m, a part of its programme of creating a local eMarketplace. The firm was purchased using Yell's existing cash reserves. Retention bonuses of as much as £5.2m will be paid to key Moonfruit management after two years, provided that they remain exclusively employed by Yell. In a statement Yell said: "The deal is a significant move in Yell's ongoing transformation from its established position in providing print and online advertising for small and medium-sized enterprises (SMEs) to become a leader in the emerging local eMarketplace." Source BioScience, a diagnostics and genetic analysis business, has enjoyed a period of sustained growth and development during the first three months of 2012. Revenue saw a double digit percentage increase compared with the same period last year, boosted by significant progression of LifeSciences' DNA sequencing services and Healthcare's cervical cancer screening business. Trading was in line with management expectations and the group remains in a robust financial position with £1.7m of cash at the end of March 2012 (31 December 2011: £1.1m).NR
More News
23 Feb 2016 16:05

ReNeuron moving to purpose-built labs in Wales

(ShareCast News) - ReNeuron's office, laboratory and manufacturing staff were preparing for a space upgrade this week, with the firm announcing it was moving from Guildford to Pencoed in South Wales. The AIM-traded stem cell therapy development company said the new location was purpose-built, and wo

Read more
23 Feb 2016 09:16

ReNeuron Relocating Headquarters To South Wales Business Park

Read more
3 Feb 2016 15:15

Babcock non-exec picks up some shares

(ShareCast News) - Engineering support services company Babcock International said non-executive director Jeff Randall purchased 1,134 shares at 8.81p each. This brings his total holding to 4,268 shares. On Tuesday, Babcock said its joint venture with Lockheed Martin, Ascent Flight Training, had

Read more
3 Feb 2016 11:18

DIRECTOR DEALINGS: ReNeuron Group Chairman Ups Interest

Read more
1 Feb 2016 09:15

ReNeuron Gets Notice Of Grant For US Cell Cryopreservation Patent

Read more
12 Jan 2016 10:06

ReNeuron Greets Exosome Nanomedicine Data Publication In Journal

Read more
11 Jan 2016 08:07

ReNeuron Group Wins UK Grant For Its Exosome Nanomedicine Platform

Read more
7 Dec 2015 09:30

ReNeuron First Half Loss Widens As It Progresses Clinical Development

Read more
4 Dec 2015 09:15

ReNeuron Group Appoints Ex-Glaxo Executive Owen To Board

Read more
24 Sep 2015 10:39

ReNeuron Says Fundraising Will Allow It To Develop Clinical Pipeline (ALLISS)

Read more
17 Sep 2015 15:09

AGM, EGM Calendar - Week Ahead

Read more
21 Aug 2015 07:29

LONDON BRIEFING: China And Greece Combine To Send Stocks Reeling

Read more
21 Aug 2015 05:17

AGM, EGM Calendar - Week Ahead

Read more
20 Aug 2015 15:14

AGM, EGM Calendar - Week Ahead

Read more
20 Aug 2015 05:19

AGM, EGM Calendar - Week Ahead

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.